<DOC>
	<DOCNO>NCT00865020</DOCNO>
	<brief_summary>This study specifically design provide additional information mechanism action direct renin inhibition postulate higher-level RAS cascade inhibition . The purpose study compare prolong efficacy safety aliskiren telmisartan mild moderate hypertensive patient 24 hrs Ambulatory Blood Pressure Monitoring set one week treatment withdrawal .</brief_summary>
	<brief_title>Efficacy Safety Aliskiren 300 mg Compared Telmisartan 80 mg After 1 Week Treatment Withdrawal</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Mean sit systolic blood pressure ≥ 140 mmHg &lt; 180 mmHg 24hr mean ambulatory systolic blood pressure ≥ 135 mmHg Severe hypertension define mean sit systolic blood pressure ≥ 180 mmHg and/or mean sit diastolic blood pressure ≥ 110 mmHg Patients Type 1 diabetes mellitus Secondary hypertension etiology Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>ABPM</keyword>
	<keyword>systolic blood pressure</keyword>
	<keyword>diastolic blood pressure</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>aliskiren</keyword>
	<keyword>telmisartan</keyword>
</DOC>